Novaremed seeks FDA nod for evaluating NRD135S.E1 for treatment of PDPN

This article was originally published here

In this connection, Novaremed has filed an investigational new drug (IND) application to the FDA. The clinical-stage Swiss biopharma company revealed to have got initial feedback from the

The post Novaremed seeks FDA nod for evaluating NRD135S.E1 for treatment of PDPN appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply